The Valens Company (TSX | NASDAQ: VLNS) is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company, founded in 2014, provides proprietary cannabis processing services, along with product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products cater to the medical, health and wellness, and recreational consumer segments, across all cannabis product categories, with a focus on quality and innovation. Through Valens Labs, the Company is setting the standard in cannabis testing and research with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. The Valens Company was acquired by SNDL Inc. in January of 2023, and continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. For more information on Valens Business Services, visit The Valens Company website. For more information on SNDL, visit sndl.com.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Post-IPO Equity | Unknown | - | 29 Mar 2022 | |
Post-IPO Debt | Unknown | - | 16 Dec 2021 | |
Post-IPO Equity | Unknown | - | 01 Jun 2021 | |
Post-IPO Equity | Unknown | - | 25 Jan 2021 | |
Post-IPO Debt | Unknown | - | 01 Jun 2020 |
No recent news or press coverage available for The Valens Company.